ATE396982T1 - Phenylfuranverbindungen als modulatoren des vitamin-d-rezeptors - Google Patents

Phenylfuranverbindungen als modulatoren des vitamin-d-rezeptors

Info

Publication number: ATE396982T1
Authority: AT; Austria
Prior art keywords: vitamin; compounds; receptor; phenylfuran; modulators
Prior art date: 2003-11-20

Application number

AT04810027T

Other languages

English (en)

Inventor

Robert Gajewski

Charles Jones

Jianliang Lu

Tianwei Ma

Sunil Nagpal

Ying Yee

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-20

Filing date

2004-11-16

Publication date

2008-06-15

2004-11-16 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2008-06-15 Application granted granted Critical

2008-06-15 Publication of ATE396982T1 publication Critical patent/ATE396982T1/de

Links

102000009310 vitamin D receptors Human genes 0.000 title abstract 3
108050000156 vitamin D receptors Proteins 0.000 title abstract 3
150000005353 phenylfurans Chemical class 0.000 title abstract 2
GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 abstract 1
208000020084 Bone disease Diseases 0.000 abstract 1
201000004681 Psoriasis Diseases 0.000 abstract 1
235000020964 calcitriol Nutrition 0.000 abstract 1
239000011612 calcitriol Substances 0.000 abstract 1
GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000000121 hypercalcemic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Hematology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Oncology (AREA)
Reproductive Health (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Toxicology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Furan Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Liquid Crystal Substances (AREA)
Pyrane Compounds (AREA)

AT04810027T 2003-11-20 2004-11-16 Phenylfuranverbindungen als modulatoren des vitamin-d-rezeptors ATE396982T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US52401503P	2003-11-20	2003-11-20

Publications (1)

Publication Number	Publication Date
ATE396982T1 true ATE396982T1 (de)	2008-06-15

Family

ID=34632855

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04810027T ATE396982T1 (de)	2003-11-20	2004-11-16	Phenylfuranverbindungen als modulatoren des vitamin-d-rezeptors

Country Status (8)

Country	Link
US (1)	US7468449B2 (de)
EP (1)	EP1692123B1 (de)
JP (1)	JP4750713B2 (de)
AT (1)	ATE396982T1 (de)
CA (1)	CA2546729A1 (de)
DE (1)	DE602004014188D1 (de)
ES (1)	ES2307069T3 (de)
WO (1)	WO2005051936A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI1511740T1 (sl) *	2002-05-29	2009-12-31	Lilly Co Eli	Modulatorji vitamin d receptorja tipa fenil-tiofen
DE60326082D1 (de)	2002-11-22	2009-03-19	Lilly Co Eli	Modulatoren von vitamin d rezeptoren
CA2544857A1 (en)	2003-11-20	2005-06-09	Eli Lilly And Company	Vitamin d receptor modulators
ES2291981T3 (es) *	2003-11-20	2008-03-01	Eli Lilly And Company	Moduladores del receptor de la vitamina d.
US7595345B2 (en)	2003-11-20	2009-09-29	Eli Lilly And Company	Vitamin D receptor modulators
WO2005051936A1 (en)	2003-11-20	2005-06-09	Eli Lilly And Company	Phenyl-furan compounds as vitamin d receptor modulators
WO2005051898A2 (en)	2003-11-20	2005-06-09	Eli Lilly And Company	Vitamin d receptor modulators
DK1836151T3 (da) *	2004-12-21	2009-06-02	Lilly Co Eli	D-vitamin-receptormodulatorer
CA2589667A1 (en) *	2004-12-21	2006-06-29	Eli Lilly And Company	Vitamin d receptor modulators
US9370527B2 (en)	2012-12-28	2016-06-21	The Regents Of The University Of Michigan	Amelioration of intestinal fibrosis and treatment of Crohn's disease
CN103193695B (zh) *	2013-04-22	2015-08-05	中国药科大学	3-苯基-3-吡咯基戊烷类衍生物及其医药用途
WO2017079718A1 (en)	2015-11-06	2017-05-11	Regents Of The University Of Minnesota	Methods of forming aromatic containing compounds
US11236057B2 (en)	2015-11-06	2022-02-01	Regents Of The University Of Minnesota	Aromatic surfactants
CN106908559B (zh) *	2015-12-23	2020-08-11	重庆华邦胜凯制药有限公司	卡泊三醇中间体l及相关杂质的分离与测定方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4282246A (en) *	1980-03-07	1981-08-04	Pfizer Inc.	Antidiabetic furancarboxylic and thiphenecarboxylic acids
US6218430B1 (en) *	1998-08-24	2001-04-17	Ligand Pharmaceuticals Incorporated	Vitamin D3 mimics
SI1511740T1 (sl)	2002-05-29	2009-12-31	Lilly Co Eli	Modulatorji vitamin d receptorja tipa fenil-tiofen
DE10229456A1 (de) *	2002-07-01	2004-02-05	Wank, Rudolf, Prof. Dr.med.	Verwendung von Dopamin-Rezeptor-Agonisten zur Behandlung von Hautgeschwülsten und Warzen
EP1587906A2 (de)	2003-01-10	2005-10-26	Eli Lilly And Company	Vesikansbehandlung mit vitamin-d-rezeptormodulatoren des phenyl-phenyl-typs
WO2004063348A2 (en)	2003-01-10	2004-07-29	Eli Lilly And Company	Vesicant treatment with phenyl-thiophene type vitamin d receptor modulators
ES2291981T3 (es) *	2003-11-20	2008-03-01	Eli Lilly And Company	Moduladores del receptor de la vitamina d.
US7595345B2 (en)	2003-11-20	2009-09-29	Eli Lilly And Company	Vitamin D receptor modulators
CA2544857A1 (en) *	2003-11-20	2005-06-09	Eli Lilly And Company	Vitamin d receptor modulators
WO2005051936A1 (en)	2003-11-20	2005-06-09	Eli Lilly And Company	Phenyl-furan compounds as vitamin d receptor modulators
WO2005051898A2 (en)	2003-11-20	2005-06-09	Eli Lilly And Company	Vitamin d receptor modulators

2004
- 2004-11-16 WO PCT/US2004/035527 patent/WO2005051936A1/en not_active Ceased
- 2004-11-16 EP EP04810027A patent/EP1692123B1/de not_active Expired - Lifetime
- 2004-11-16 US US10/578,991 patent/US7468449B2/en not_active Expired - Fee Related
- 2004-11-16 ES ES04810027T patent/ES2307069T3/es not_active Expired - Lifetime
- 2004-11-16 JP JP2006541190A patent/JP4750713B2/ja not_active Expired - Fee Related
- 2004-11-16 CA CA002546729A patent/CA2546729A1/en not_active Abandoned
- 2004-11-16 AT AT04810027T patent/ATE396982T1/de not_active IP Right Cessation
- 2004-11-16 DE DE602004014188T patent/DE602004014188D1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP1692123A1 (de)	2006-08-23
EP1692123B1 (de)	2008-05-28
WO2005051936A1 (en)	2005-06-09
DE602004014188D1 (de)	2008-07-10
US7468449B2 (en)	2008-12-23
JP2007512326A (ja)	2007-05-17
ES2307069T3 (es)	2008-11-16
JP4750713B2 (ja)	2011-08-17
CA2546729A1 (en)	2005-06-09
US20070105951A1 (en)	2007-05-10

Legal Events

Date	Code	Title	Description
2008-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
CY1108988T1 (el)	2014-07-02	Διαμορφωτες υποδοχεα βιταμινης d
CY1109341T1 (el)	2014-07-02	Διαμορφωτες υποδοχεα βιταμινης d τυπου φαινυλο-θειοφαινιου
ATE396982T1 (de)	2008-06-15	Phenylfuranverbindungen als modulatoren des vitamin-d-rezeptors
ATE370941T1 (de)	2007-09-15	Modulatoren des vitamin-d-rezeptors
UA83194C2 (ru)	2008-06-25	Производные пиримидина и их применение как модуляторов св2
ATE534293T1 (de)	2011-12-15	Diarylaminhaltige verbindungen und zusammensetzungen und deren verwendung als modulatoren von c-kit-rezeptoren
MX2010002674A (es)	2010-03-25	Moduladores de gamma secretasa.
EA200301232A1 (ru)	2004-04-29	Новые соединения арилсульфонамида и их применение для лечения ожирения, диабета типа ii и нарушений центральной нервной системы
MY140767A (en)	2010-01-15	Compounds, methods and compositions
DE60309739D1 (de)	2006-12-28	Pyridinderivate als modulatoren des cb2-rezeptors
MX2010005028A (es)	2010-05-27	Moduladores de gamma secretasa.
PA8493701A1 (es)	2002-07-30	Compuestos para tratar la obesidad
CY1110555T1 (el)	2015-04-29	4-((φαινοξυαλκυλ)θειο)-φαινοξυοξεικα οξεα και αναλογα
BR0309278A (pt)	2005-04-26	Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
ATE429645T1 (de)	2009-05-15	Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
WO2005051893A3 (en)	2005-07-14	Vitamin d receptor modulators
AU2003233735A8 (en)	2003-12-31	24-sulfoximine vitamin d3 compounds
ATE537834T1 (de)	2012-01-15	2-methylen-19-nor-vitamin d2-verbindungen
ATE340785T1 (de)	2006-10-15	2-phenylamino-4-trifluoromethyl-5-(benzyl- oder pyridin-4-ylmethyl)carbamoylpyrimidin-derivate als selektive cb2 cannabinoid-rezeptor modulatoren
EP1539727A4 (de)	2007-04-04	Verbindungen, zusammensetzungen und verfahren
BR0315247A (pt)	2005-08-30	Composição, composição farmacêutica, método de tratamento para uma doença proliferativa celular, e, kit
ATE455749T1 (de)	2010-02-15	Verbindungen mit verbrückten ringen als pharmazeutische mittel
ATE509269T1 (de)	2011-05-15	Verfahren und verbindungen zur modulierung von apoptosis
GB0324656D0 (en)	2003-11-26	A protein involved in ovarian cancer
EA200601267A1 (ru)	2006-12-29	Модуляторы рецепторов андрогена